Gsk earnings were $4.6B for the trailing 12 months ending Jun 30, 2025, with -8.4% growth year over year. The latest GSK earnings report on Jun 30, 2025 announced Q2 2025 earnings of $2.0B, down 6.3% from last quarter. For the last reported fiscal year 2024 ending Dec 31, 2024, GSK reported annual earnings of $3.2B, with -48.4% growth.
GSK past earnings growth
How has GSK's earnings growth performed historically?
On GSK's earnings call on Invalid Date, Gsk (NYSE: GSK) reported Q2 2025 earnings per share (EPS) of $0.97, up 33.47% year over year. Total GSK earnings for the quarter were $1.98 billion. In the same quarter last year, Gsk's earnings per share (EPS) was $0.73.
As of the last Gsk earnings report, Gsk is currently profitable. Gsk's net profit (also called net income) for the twelve months ending Jun 30, 2025 was $4.69 billion, a 8.15% decrease year over year.
What was GSK's earnings growth in the past year?
As of Gsk's earnings date in Invalid Date, Gsk's earnings has grown -8.36% year over year. This is 59.51 percentage points lower than the US Drug Manufacturers - General industry earnings growth rate of 51.15%. GSK earnings in the past year totalled $4.63 billion.
WallStreetZen does not provide financial advice and does not issue recommendations or offers to buy stock or sell any security.
Information is provided 'as-is' and solely for informational purposes and is not advice. WallStreetZen does not bear any responsibility for any losses or damage that may occur as a result of reliance on this data.